Trial of Docetaxel and Irinotecan (DI) for Recurrent or Refractory Bone and Soft Tissue Sarcomas.

NCT01380275 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

35

Enrollment

OTHER_GOV

Sponsor class

Conditions

Sarcoma

Interventions

DRUG: Docetaxel (Taxotere)
DRUG: Irinotecan

Sponsor

National Cancer Center, Korea